Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs ARQ 092 (Primary)
- Indications Proteus syndrome
- Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
- 20 Jan 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
- 20 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.
- 07 Nov 2016 According to ArQule media release, assessment of full data from the initial two cohorts will be in the early part of next year.